Get the Stockscreener App
0.6801
2.82%
-0.0197
Pre-market:
.68
-0.000100
-0.01%
Pasithea Therapeutics Corp stock is traded at $0.6801, with a volume of 167.68K.
It is down -2.82% in the last 24 hours and down -1.43% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
See More
Previous Close:
$0.6998
Open:
$0.72
24h Volume:
167.68K
Relative Volume:
0.42
Market Cap:
$22.73M
Revenue:
-
Net Income/Loss:
$-20.43M
P/E Ratio:
-0.1906
EPS:
-3.5677
Net Cash Flow:
$-15.21M
1W Performance:
-3.20%
1M Performance:
-1.43%
6M Performance:
-35.84%
1Y Performance:
-25.70%
1-Day Range:
$0.68
$0.72
1-Week Range:
$0.68
$0.742
52-Week Range:
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.6801 | 23.38M | 0 | -20.43M | -15.21M | -3.5677 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Significant EPS Beat Despite Zero RevenueHigh Interest Stocks - Newser
KTTA Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock SlipsEarnings Seasonality - Newser
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained - TipRanks
Pasithea Therapeutics Corp.Common Stock (NQ: KTTA - The Chronicle-Journal
Pasithea Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea Therapeutics Corp. 1Q 2026: Net loss $(2.87M), EPS $(0.12) — 10-Q Summary - TradingView
Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pasithea Therapeutics (NASDAQ: KTTA) ramps PAS-004 R&D on $50M cash base - Stock Titan
Ameriprise (KTTA) reports 1.35M-share, 5.4% stake in Pasithea Therapeutics - Stock Titan
TradingKey - TradingKey
Pasithea Therapeutics appoints chief medical officer - MSN
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Pasithea Therapeutics (KTTA) CEO awarded 1.76M stock options at $0.841 - Stock Titan
Pasithea (NASDAQ: KTTA) grants director 152,783 options at $0.841 strike - Stock Titan
Pasithea Therapeutics (KTTA) director receives 152,783 stock options grant - Stock Titan
Pasithea Therapeutics (KTTA) CFO receives 1.13M-share stock option grant - Stock Titan
[Form 4] Pasithea Therapeutics Corp. Insider Trading Activity - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) grants director Emer Leahy 152,783 options - Stock Titan
Pasithea (KTTA) director receives 152,783 stock options at $0.841 - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) names Chief Medical Officer as reporting insider on Form 3 - Stock Titan
Pasithea Therapeutics Appoints Dr. Kartik Krishnan as Chief Medical Officer to Advance PAS-004 MEK Inhibitor for NF1 and Rare Diseases 12 - Minichart
8-K: Current report - Moomoo
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives - TipRanks
New CMO and large option grants at Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - Investing News Network
Pasithea names Kartik Krishnan as chief medical officer By Investing.com - Investing.com South Africa
Pasithea Therapeutics Appoints Kartik Krishnan as Chief Medical Officer - citybiz
Pasithea names Kartik Krishnan as chief medical officer - Investing.com
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Funicular Funds (KTTA) reports 1.84M shares, 7.4% stake in Pasithea (KTTA) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Pasithea Therapeutics Corp (KTTA) - The Globe and Mail
KTTA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 - Investing News Network
FDA grants rare pediatric disease status to Pasithea’s PAS-004 By Investing.com - Investing.com South Africa
FDA grants rare pediatric disease status to Pasithea’s PAS-004 - Investing.com
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) - ChartMill
Pasithea Therapeutics (KTTA) Stock Employment Data (Grinds Lower) 2026-04-20Gap Up Stocks - Newser
Coastlands Capital reveals KTTA (NASDAQ: KTTA) stake in shares and pre-funded warrants - Stock Titan
Form 3Initial statement of beneficial ownership of securities - ADVFN
Can Pasithea Therapeutics Corp grow without external funding2026 Momentum Check & Verified Short-Term Plans - baoquankhu1.vn
Should you buy the dip on Pasithea Therapeutics Corp2026 Weekly Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Loss Report: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantPortfolio Gains Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Wrap: Can Pasithea Therapeutics Corp grow without external funding2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Is Pasithea Therapeutics (KTTA) Stock Good for Passive Investors | Price at $0.76, Down 0.52%Growth ETF - Newser
Opaleye/James Silverman hold 2.49M shares of Pasithea (KTTA) in Schedule 13G - Stock Titan
Aug Opening: Whats the beta of Pasithea Therapeutics Corp stockTreasury Yields & Daily Chart Pattern Signals - baoquankhu1.vn
Buyback Watch: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pasithea Therapeutics Corp Stock (KTTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):